Tuberculosis diagnostics
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- UNIVERSIDAD DE LA FRONTERA
Chilean university bridging European and Latin American research in cancer prevention, TB diagnostics, and biopolymer food technologies.
“INNOVA4TB targets latent TB detection and genotypic drug susceptibility testing, areas where Latin American clinical populations provide critical data.”
CL5 projects - EMPE DIAGNOSTICS AB
Swedish SME building rapid molecular diagnostic platforms to detect drug-resistant tuberculosis and other infectious diseases.
“All three H2020 projects (INNOVA4TB, mfloDx Phase 1, mfloDx Phase 2) focus on TB detection and drug resistance profiling.”
PrimarySMESE3 projects - PROTEINLOGIC LIMITED
Cambridge biotech SME developing and clinically validating protein biomarker diagnostics, notably for active tuberculosis and cancer susceptibility.
“Coordinated ADVANTAGE (EUR 3M), validating a novel diagnostic for active TB disease across European clinical sites.”
PrimarySMEUK2 projects